Samsung Biologics Co.,Ltd.

KOSE:A207940 Stock Report

Market Cap: ₩66.8t

Samsung BiologicsLtd Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

John Chongbo Rim

Chief executive officer

₩6.6b

Total compensation

CEO salary percentage18.2%
CEO tenure4yrs
CEO ownershipn/a
Management average tenure1.9yrs
Board average tenure4.8yrs

Recent management updates

Recent updates

These 4 Measures Indicate That Samsung BiologicsLtd (KRX:207940) Is Using Debt Reasonably Well

Dec 24
These 4 Measures Indicate That Samsung BiologicsLtd (KRX:207940) Is Using Debt Reasonably Well

Samsung Biologics Co.,Ltd. (KRX:207940) Investors Are Less Pessimistic Than Expected

Nov 11
Samsung Biologics Co.,Ltd. (KRX:207940) Investors Are Less Pessimistic Than Expected

These 4 Measures Indicate That Samsung BiologicsLtd (KRX:207940) Is Using Debt Reasonably Well

Sep 09
These 4 Measures Indicate That Samsung BiologicsLtd (KRX:207940) Is Using Debt Reasonably Well

Samsung Biologics Co.,Ltd.'s (KRX:207940) 26% Share Price Surge Not Quite Adding Up

Jul 29
Samsung Biologics Co.,Ltd.'s (KRX:207940) 26% Share Price Surge Not Quite Adding Up

Does Samsung BiologicsLtd (KRX:207940) Have A Healthy Balance Sheet?

May 27
Does Samsung BiologicsLtd (KRX:207940) Have A Healthy Balance Sheet?

What Samsung Biologics Co.,Ltd.'s (KRX:207940) P/E Is Not Telling You

Apr 14
What Samsung Biologics Co.,Ltd.'s (KRX:207940) P/E Is Not Telling You

CEO Compensation Analysis

How has John Chongbo Rim's remuneration changed compared to Samsung BiologicsLtd's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

₩1t

Jun 30 2024n/an/a

₩1t

Mar 31 2024n/an/a

₩895b

Dec 31 2023₩7b₩1b

₩858b

Sep 30 2023n/an/a

₩937b

Jun 30 2023n/an/a

₩826b

Mar 31 2023n/an/a

₩793b

Dec 31 2022₩5b₩1b

₩798b

Sep 30 2022n/an/a

₩507b

Jun 30 2022n/an/a

₩510b

Mar 31 2022n/an/a

₩480b

Dec 31 2021₩3b₩598m

₩394b

Sep 30 2021n/an/a

₩410b

Jun 30 2021n/an/a

₩335b

Mar 31 2021n/an/a

₩265b

Dec 31 2020₩995m₩421m

₩241b

Sep 30 2020n/an/a

₩355b

Jun 30 2020n/an/a

₩343b

Mar 31 2020n/an/a

₩278b

Dec 31 2019₩1b₩497m

₩203b

Compensation vs Market: John Chongbo's total compensation ($USD4.52M) is above average for companies of similar size in the KR market ($USD1.25M).

Compensation vs Earnings: John Chongbo's compensation has increased by more than 20% in the past year.

CEO

John Chongbo Rim (63 yo)

4yrs

Tenure

₩6,600,000,000

Compensation

Mr. John Chongbo Rim serves as Chairman of Samsung Biologics Co.,Ltd. since March 17, 2023. He has been the CEO & President of Samsung Biologics Co.,Ltd.since December 16, 2020. Mr. Rim has been Director...

Leadership Team

NamePositionTenureCompensationOwnership
John Chongbo Rim
CEO, President & Chairman of Board4yrs₩6.60bno data
Dong-Joong Kim
CFO, Executive VP10yrs₩1.20b0.0065%
₩ 4.3b
Kun Lo
Executive VPno data₩879.50mno data
Pierre Catignol
Executive VP & Head of Operation Centerless than a yearno datano data
Namjin Chung
Executive VP and Head of Bio R&D Centre & CSO2yrsno datano data
James J. Choi
Executive VP1.9yrs₩569.00mno data
Kyuho Lee
Executive VPless than a yearno datano data
Brian Hosung Min
Executive VP & Head of CDO Development Center1.9yrsno datano data
Doyoung Heo
Vice President & Head of Financeno datano datano data
Heekyun Lim
VP & Head of Business Consulting Teamno datano datano data
Yong Park
VP & Head of HR Planning Departmentless than a yearno datano data
Sangwon Seo
VP and Head of Sales & Operation Departmentno datano datano data

1.9yrs

Average Tenure

56.5yo

Average Age

Experienced Management: A207940's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
John Chongbo Rim
CEO, President & Chairman of Board4.8yrs₩6.60bno data
Dong-Joong Kim
CFO, Executive VP5.8yrs₩1.20b0.0065%
₩ 4.3b
Kun Lo
Executive VP1.8yrs₩879.50mno data
Kyonghee Kim
Independent Outside Director4.8yrsno datano data
Changwoo Lee
Independent Directorno datano datano data
Geunnyeong Heo
Independent Director5.8yrsno datano data
Seoung Hwan Suh
Independent Directorless than a yearno datano data

4.8yrs

Average Tenure

62yo

Average Age

Experienced Board: A207940's board of directors are considered experienced (4.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 13:00
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Samsung Biologics Co.,Ltd. is covered by 49 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Girish BakhruBofA Global Research
Hyung Soo KimCape Investment & Securities Co., Ltd.
Hyeryeong KimCGS International